LIST and Myelin-H are bringing multiple sclerosis monitoring home

The Luxembourg Institute of Science and Technology (LIST) and Myelin-H sarl have joined forces to develop a healthcare solution that brings the hospital into patients' homes, making multiple sclerosis monitoring and rehabilitation more accessible, accurate, and personalized.

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the myelin sheath—the protective coating around nerve fibres. This disruption slows or blocks the transmission of electrical signals in the nervous system, leading to a wide range of symptoms, from fatigue to severe mobility challenges. Managing MS is a significant challenge, with 42% of patients receiving inadequate treatment and annual healthcare costs reaching up to $100,000 per person in advanced cases.

How remote monitoring could transform multiple sclerosis treatment

Currently, the gold standard for monitoring MS involves magnetic resonance imaging (MRI) and biomarker analysis. While effective, MRI scans are expensive, time-consuming, and often require hospitalisation. For many patients, these barriers result in delayed interventions and poorly tailored treatments.

Dr Zied Tayeb, Founder & CEO of Myelin-H, said:

"Myelin-H has developed an innovative Software-as-a-Medical Device (SaMD) for real-time, remote monitoring and neurorehabilitation of MS patients. This brain-computer interface platform integrates mobile cognitive games, wearable sensors, and advanced machine learning to enable patients to track their condition from the comfort of their homes. As part of the R-MMS project, this SaMD will undergo clinical validation by benchmarking its novel remote monitoring approach against established gold standards and common clinical practices, including MRI, EDSS scores, and blood tests."

In practice, patients engage with neuroscience-based games on their smartphones or tablets, while wearable devices collect biosignals such as brain activity, muscle function, and speech patterns. These signals are processed by a biologically inspired machine learning engine - a technology modelled on the human brain - to generate a comprehensive clinical score. Physicians can access this data via a real-time dashboard, enabling them to adjust treatments, predict relapses, and intervene early when necessary. In addition to monitoring, the platform also generates personalised game-based neurorehabilitation programmes. These programmes, informed by monitoring scores, target cognitive and physical symptoms by leveraging neuroplasticity, complementing pharmacological treatments to enhance patient outcomes.

Djamel Khadraoui, Leader of the Reliable Distributed Systems research unit, stated:

“We will develop a privacy enhancing technologies for the state-of-the-art SaMD software to comply with the regulations and standards such as the European GDPR and enable this software to operate on multiple clinical sites located in Italy, Belgium, the Netherlands, the UK and the USA. Hence, the impact of the project will go beyond the borders of Luxembourg and the European health ecosystem.”

Lucien Hoffmann, Scientific Director at LIST, said:

“This project reflects our commitment to creating practical, patient-centered solutions. Here, we are not only improving lives but also paving the way for more efficient healthcare systems.”

A model for digital healthcare

The success of the R-MMS project could extend far beyond multiple sclerosis. Its technology could be adapted for other neurodegenerative diseases like Parkinson’s, setting a precedent for remote, AI-driven healthcare.

With its blend of high-tech innovation and patient-centered design, R-MMS stands poised to redefine what’s possible in healthcare. As the trials progress, all eyes will be on Luxembourg and its team of visionary researchers.

Visit the dedicated research page on R-MMS: Remote Monitoring of Multiple Sclerosis